Stock IRON DISC MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Disc Medicine, Inc.

Equities

IRON

US2546041011

Market Closed - Nasdaq
Other stock markets
 21:00:00 13/05/2024 BST 		5-day change 1st Jan Change
31.01 USD +2.14% Intraday chart for Disc Medicine, Inc. +2.78% -46.31%
05-09 Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-08 Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
GL
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
AQ
Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating
MT
Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating
MT
Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating
MT
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating
MT
Stifel Adjusts Price Target on Disc Medicine to $71 From $104, Keeps Buy Rating
MT
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept
MT
North American Morning Briefing : Stocks Seen -2-
DJ
Top Midday Decliners
MT
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge
MT
Raymond James Downgrades Disc Medicine to Outperform From Strong Buy, Cuts Price Target to $40 From $75
MT
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
GL
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria
CI
Wedbush Raises Disc Medicine Price Target to $84 From $79, Maintains Outperform Rating
MT
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Stifel Adjusts Price Target on Disc Medicine to $104 From $76, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IRON Stock
  4. News Disc Medicine, Inc.